Autogenomics

AutoGenomics, Inc. has developed one of the first automated microarray based multiplexing molecular diagnostic platforms that can be used to assess disease signatures with novel genomic markers in the area of infectious diseases, pharmacogenetics, cancer and genetic disorders.
With discovery of genes and their link to various disease states the INFINITI® platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the new era of personalized medicine.

Seegene

Founded in 2000 and based in Rockville (USA) and Seoul, Korea, Seegene, Inc. is pioneering the field of multi-pathogen testing. Seegene specializes in oligonucleotide assays and two core technologies named DPO™ (Dual Priming Oligonucleotide) and READ™ (REal Amplicon Detection), which maximize the sensitivity and specificity of PCR. These breakthrough technologies have been applied in various fields and yielded significant achievements. Seegene applies Seeplex®, Anyplex™ and Magicplex™ its breakthrough multiplexing PCR technology platforms, that enables a new standard in simultaneous multi-pathogen detection delivering maximum specificity, reproducibility and sensitivity. Seegene, Inc. obtained ISO9001 and ISO13485 certification.

Ikonisys

Ikonisys, Inc. is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping researchers and physicians realize the promise of rare cell detection to give patients the best chance of managing their disease.
Most exciting, through its integration of intelligent imaging, microscopy, biology and informatics, Ikonisys is laying the foundation for detecting a single cell and identifying its molecular signals, a long-term key to maximizing patient health and wellness.

LINKS

AutoGenomics

Seegene

Ikonisys